Hodgkin lymphoma (HL) is an aggressive lymphoma of B-cell origin that was initially described by British pathologist Thomas Hodgkin in 1832. Since its initial clinical characterization and subsequent discovery that it is a clonal neoplasm of atypical B lymphocytes, research has led to curative therapy for all stages of this disease. Reflecting this, 5-year survival rates have steadily risen over the decades from 72% (1975–1977) to 84% (1995–1997) to 89% (2012–2018) [1]. Though HL has previously been divided into classic HL and nodular lymphocyte predominant HL, these are not subdivisions that share a common taxonomical hierarchy, either by disease biology or clinical management. The international consensus classification has thus renamed this latter entity as nodular lymphocyte predominant B-cell lymphoma [2]. As such, this review is centered on classic HL, focusing on the current treatment paradigms and the recent advancements which call these paradigms into question.